This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): copolymer-1, glatiramer acetate
Description: Copaxone (Glatiramer acetate) is an approved drug for the treatment of multiple sclerosis. It is a synthetic analog of myelin basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal cord. It binds to MHC molecules on T cells, preventing native myelin antigens from binding to these T cells and consequent attacks on myelin-covered nerve fibers.
Deal Structure: In February 1999, AutoImmune announced the signing of an exclusive agreement with Teva Pharmaceuticals for two applications of its proprietary technology for oral immune modulation. The agreement covers the development by Teva of an oral formulation of Copaxone.
In February 2001, Teva Pharmaceutical Industries announced the conclusion of an agreement with H. Lundbeck A/S to extend their existing strategic cooperation to include the oral formulation of Copaxone.
Partners: Sanofi AutoImmune Inc. H. Lundbeck A/S
Oral Copaxone News
Pink Sheet Teva terminates oral Copaxone program
Additional information available to subscribers only: